Professional Documents
Culture Documents
Q2 2017
January 23, 2017
2017 ResMed I 2
Long-term growth
opportunities across all three horizons
of ResMeds strategy
Proven innovator
in products and Connected Care for sleep apnea, COPD,
neuromuscular disease and other chronic diseases
Underpenetrated markets
For sleep-disordered breathing and respiratory care
2017 ResMed I 3
Disciplined financial
management
Operational excellence,
strong capital deployment history,
committed to investing in innovation and
returning excess cash to shareholders
Horizon 1
Lead SDB Industry
Ground breaking end-to-end
connected care solutions
Horizon 3
Invest in Portfolio of
New Market Options
Sleep & Consumer Wellness
Horizon 2
Scale-Up Respiratory Care
and Connected COPD
Connected respiratory care solutions
for COPD, obesity-hypoventilation
syndrome, and neuromuscular
disease, including ALS
Integrate with connected solutions
Expansion in High Growth Markets China, E. Europe, India, Brazil, S.E. Asia
2017 ResMed I 4
AirSense 10
2017 ResMed I 5
myAir
AirViewTM
2017 ResMed I 6
Activox
Bilevel Ventilation
AirCurve 10
Lumis
Stellar
Patient Acuity
2017 ResMed I 7
Astral
Over 2 million cloud-connected med devices liberating data daily through AirView
3rd Party
Diagnostics
DIAGNOSIS
2017 ResMed I 8
THERAPY
PATIENT ENGAGEMENT
AirView hasover
4million+patients
200,000+ diagnostictests
processedinthecloud
15APIcallspersecond
fromintegrators
2017 ResMed I 9
2 million+patients
monitoredathomewith
connectedcare
Brightree has45million+
patientaccountsaspartofits
postacutecarenetwork
1,000+ patientsaday
signupfor myAir
2017 ResMed I 10
Eastern Europe
China
South Korea
India
Brazil
<15% penetration
2017 ResMed I 11
<10% penetration
<1% penetration
1World
Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16
Ferkol T et al. Annals ATS 2014
estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China Respiratory and Critical Care
4 European Respiratory Society, European Lung White Book http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/ accessed 20Jul16
5 Guarascio et al. Dove Med Press, 2013 Jun 17
6 World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20Jul16
2
3 Company
2017 ResMed I 12
$10,000
8,713
$8,000
6,325
$6,000
4,819
3,713
$4,000
3,077
3,235
3,866
4,124
4,904
4,351
3,453
$2,000
$0
Source: Organization for Economic Cooperation and Development, OECD Health Statistics 2015, July 2015. As compiled by the Peter G. Peterson Foundation. Per capita
health expenditures all from 2013, except Australia for which 2012 data are the latest available. Chart uses purchasing power parities to convert data into U.S. dollars
2017 ResMed I 13
%
21
patient adherence
with automated
compliance
coaching1
1.
2.
3.
4.
Labor
Costs2
New
Patient
Setups3
2017 ResMed I 14
59%
55%
%
24
patient adherence
with patient
engagement4
2017 ResMed I 15
Control Group
Intervention Group
p=0.0004
0.30
Cumulative Mortality
0.40
0.20
0.10
100
200
Time
(Days after randomization)
References: Khnlein et al. Lancet Respir Med 2014
* Mortality reduction is 60% on a relative basis from 33% mortality to 12% mortality, which is 21% reduction on an absolute basis
2017 ResMed I 16
300
62%
Atrial Fibrillation
49%
Heart Failure
76%
Type 2 Diabetes
72%
2017 ResMed I 17
Drug-Resistant Hypertension
83%
Morbid Obesity
77%
$1.8
$379
$234
$1.2
2011
2016
Adjusted EPS
12%
CAGR
2011
2016
$2.68
18%
CAGR
$489
$1.49
$217
2011
Fiscal Years ended June 30
2017 ResMed I 18
2016
2011
2016
Q2 2017 results
Q2 2017
$530.4M
+17% (+18% CC)
58.3%
$131.6M
+13%
$103.3M
+1%
$0.73
0%
$119.9M
$105.2M
* Excludes for the impact of the Astral battery field safety notification expenses, release of SERVE-HF accrual, restructuring expenses, acquisition
related expenses and amortization of acquired intangible assets from their evaluation of ongoing operations.
2017 ResMed I 19
Brightree
6%
EMEA
24%
Americas
Devices
62%
57%
APAC
Masks and
Accessories
14%
37%
Invest in innovation
& unlock acquisition
value
Efficiencies in
product supply &
manufacturing
2017 ResMed I 21
ResMeds
Operating
Excellence
Process
Grow
operating
margins
Expand
Operating
Leverage
Capital Deployment
New Products
Geographic expansion
Acquisitions
Increasing Dividend
Long-term growth
opportunities across all three horizons
of ResMeds strategy
Proven innovator
in products and Connected Care for sleep apnea, COPD,
neuromuscular disease and other chronic diseases
Underpenetrated markets
For sleep-disordered breathing and respiratory care
2017 ResMed I 24
Disciplined financial
management
Operational excellence,
strong capital deployment history,
committed to investing in innovation and
returning excess cash to shareholders
2017 ResMed I 25